Nuvalent, Inc. (NUVL) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Cambridge, MA, アメリカ. 現CEOは James R. Porter.
NUVL を有する IPO日 2021-07-29, 162 名の正社員, に上場 NASDAQ Global Select, 時価総額 $7.67B.
Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted cancer therapies. The company's lead programs include NVL-520, a brain-penetrant ROS1-selective inhibitor currently in Phase I development designed to overcome drug resistance mutations, and NVL-655, a brain-penetrant ALK-selective inhibitor in Phase I/II clinical trials addressing treatment resistance and brain metastases. Founded in 2017 and headquartered in Cambridge, Massachusetts, Nuvalent is advancing precision oncology solutions for patients with ROS1 and ALK-driven cancers.
